Tumor specific targeting of intravenous 131I-chlorotoxin (TM-601) in patients with recurrent glioma

被引：0

作者：

Fiveash, J. B. ^{[1
]}

Nabors, L. B. ^{[1
]}

Raizer, J. J. ^{[1
]}

Avgeropoulos, N. ^{[1
]}

Modarresifar, H. ^{[1
]}

Shen, S. ^{[1
]}

机构：

[1] Univ Alabama, Med Ctr, Birmingham, AL 35294 USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2007年 / 69卷 / 03期

关键词：

D O I：

10.1016/j.ijrobp.2007.07.1266

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S257 / S258

页数：2

共 48 条

[11] Dosimetry of phase I/II study of intracavitary administered I-131-TM-601 peptide in patients with recurrent high-grade glioma
Shen, S
Mamelak, A
Raubitschek, A
Colcher, D
Liu, A
Rosenfeld, S
Nabors, L
Fiveash, J
Khazaeli, M
Bucholz, R
Alvarez, V
Gonda, M
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (01): : S259 - S259
[12] Dosimetry evaluation in a phase I study of intravenous 131I-TM601 in patients with recurrent or refractory somatic and/or cerebral metastatic solid tumors
Shen, S.
Fiveash, John
Raizer, Jeffrey
Senzer, Neil
Gribbin, Thomas
Avgeropoulos, Nicholas
Spies, Stewart
Bock, Amy
McGarry, Carolyn
O'Neill, Alison
JOURNAL OF NUCLEAR MEDICINE, 2009, 50
[13] Dosimetry study of a phase II multiple-dose intracavitary administration of 131I-TM601 in adult patients with recurrent high-grade glioma
Shen, S.
Nabors, L. B.
Raizer, J. J.
Fiveash, J. B.
Spies, S.
Costello, R.
O'Neill, A. M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[14] Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma
Mamelak, Adam N.
Rosenfeld, Steven
Bucholz, Richard
Raubitschek, Andrew
Nabors, L. Burt
Fiveash, John B.
Shen, Sui
Khazaeli, M. B.
Colcher, David
Liu, An
Osman, Medhat
Guthrie, Bart
Schade-Bijur, Susan
Hablitz, Diana M.
Alvarez, Vernon L.
Gonda, Matthew A.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (22) : 3644 - 3650
[15] A phase I evaluation of intravenous TM601 in recurrent glioblastoma: Use of perfusion MRI to monitor antiangiogenic effects
Akella, N. S.
Nabors, L. B.
Rosenfeld, S. S.
Chamberlain, M. C.
Mrugala, M. M.
Jacoby, D. B.
O'Neill, A. M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[16] SINGLE-VERSUS MULTIPLE-DOSE RADIOPHARMACEUTICAL INJECTIONS: DOSIMETRY ANALYSIS OF INTRACAVITARY 131I-TM601 IN HIGH-GRADE GLIOMA PATIENTS
Shen, Sui
Nabors, L. B.
Raizer, Jeff
Fiveash, John
Spies, Stewart
Costello, Ruthanna
O'Neill, Alison M.
NEURO-ONCOLOGY, 2009, 11 (05) : 663 - 663
[17] Annexin A2 is a novel molecular target for TM601, a peptide with specific tumor targeting and antiangiogenic properties
Kesavan, Kamala
Ratliff, Judson
Johnson, Eric
Dahlberg, William
Jacoby, Douglas B.
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[18] Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma
Sampson, John H.
Archer, Gary E.
Mitchell, Duane A.
Heimberger, Amy B.
Bibner, Darell D.
SEMINARS IN IMMUNOLOGY, 2008, 20 (05) : 267 - 275
[19] SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS
Peters, Katherine
Congdon, Kendra
Archer, Gary
Woodring, Sarah
Jaggers, Denise
Lipp, Eric
Healy, Patrick
Herndon, James
Soher, Brian
Vlahovic, Gordana
Johnson, Margaret
Randazzo, Dina
Desjardins, Annick
Friedman, Henry
Friedman, Allan
Ashley, David
Yan, Hai
Sampson, John
NEURO-ONCOLOGY, 2019, 21 : 8 - 8
[20] Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma
Sakai, Keiichi
Shimodaira, Shigetaka
Maejima, Shinya
Udagawa, Nobuyuki
Sano, Kenji
Higuchi, Yumiko
Koya, Terutsugu
Ochiai, Takanaga
Koide, Masanori
Uehara, Shunsuke
Nakamura, Midori
Sugiyama, Haruo
Yonemitsu, Yoshikazu
Okamoto, Masato
Hongo, Kazuhiro
JOURNAL OF NEUROSURGERY, 2015, 123 (04) : 989 - 997

← 1 2 3 4 5 →